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ience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo
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1191rug-eluting stents (DES) revolutionized the field of per-
utaneous coronary intervention (PCI) after their introduc-
ion in 2002, by significantly reducing rates of restenosis (1).
fter their introduction there was a rapid and unprece-
ented uptake of their use, such that within 3 years they
ere used in 80% to 90% of revascularization procedures in
he U.S. (2). Recently, concerns have emerged that the first
eneration of DES, coated with sirolimus and paclitaxel, are
ssociated with an increased risk of very late stent throm-
osis (1 year) when compared with bare-metal stents
BMS) (3). An everolimus-eluting stent (EES) has been
eveloped with the goal of improving the safety of DES.
See page 1236
The FUTURE (The First Use To Underscore restenosis
eduction with Everolimus) I (4,5) and FUTURE II (6)
tudies were the first to demonstrate the feasibility of using
verolimus on a DES. The SPIRIT (Clinical Evaluation of
he Xience V Everolimus Eluting Coronary Stent System in
he Treatment of Patients with de novo Native Coronary
rtery Lesions) FIRST study has subsequently demon-
trated clinical safety and efficacy of the EES out to 4 years’
ollow-up (7). In particular, significantly lower in-stent late
oss was demonstrated at 12-month angiographic follow-up,
ompared with an identical BMS (8).
The assessment of the EES continued with SPIRIT II
nd the larger SPIRIT III studies. Both involved the
andomized comparison of EES to the TAXUS (Boston
cientific, Natick, Massachusetts) paclitaxel-eluting stent
PES) in patients with a maximum of 2 de novo coronary
rtery lesions. In both studies, there was a significant reduction
n major adverse cardiac events (MACE) with EES compared
ith PES at 12-month follow-up (9,10). A “late loss catch-up”
ith EES was suggested by the 2-year outcome data from
PIRIT II that showed no significant difference in angio-
raphic and clinical outcomes between the 2 stents (11).
he 2-year follow-up data from SPIRIT III, however, has
hown promising results with improvements in event-free
urvival and lower rates of stent thrombosis with the use of
n EES (12).
The current study presents the 3-year clinical outcome of
atients enrolled in the SPIRIT II study treated with either
ES or a PES. This represents the longest available clinical
ollow-up for EES in a moderately sized population.
ethods
atient population. The patient population has been de-
cribed previously (13). In brief, SPIRIT II was a multicenter
rial enrolling 300 patients who were randomized in a ratio of
:1 to receive either an EES, XIENCE V (Abbott Vascular,
anta Clara, California) (n 223), or a PES (n 77). Both iAXUS Express2 (73% of lesions) and TAXUS Liberté
27% of lesions) were used in the control arm. A detailed
escription of everolimus and the EES is provided else-
here (13,14). The ethics committee of each participating
nstitution approved the study protocol, and all patients gave
ritten informed consent.
All patients were over the age of 18, with evidence of
yocardial ischemia and a maximum of 2 de novo native
oronary artery lesions in different major epicardial vessels. For
nclusion, on visual estimation,
arget lesion(s) were required to
e: in a vessel with a reference
essel diameter of between 2.5
nd 4.25 mm;28 mm in length;
nd have a percentage diameter
tenosis (DS) of between 50% and
9%, with a Thrombolysis In
yocardial Infarction flow grade
1. Patients with documented
vidence of recent (3 days) myo-
ardial infarction (MI); a left ven-
ricular ejection fraction 30%;
aiting heart transplantation; or
aving a known sensitivity or con-
raindications to aspirin, heparin,
ivalirudin, clopidogrel or ticlopi-
ine, cobalt, chromium, nickel,
ungsten, everolimus, paclitaxel,
crylic, and fluoropolymers were
xcluded. Angiographic lesions
nvolving the left main stem lesion
r the aorto-ostial junction; lo-
ated within 2 mm of the origin of
he left anterior descending or left
ircumflex; that were heavily cal-
ified; or that had associated visi-
le thrombus were also excluded.
tudy procedure. Patients were
andomized between EES and
ES after the identification of
uitable lesions on preliminary
ngiography. Physicians were
ot blinded, in view of the dif-
erent packaging for each stent.
tandard interventional tech-
iques were used to treat the lesion; in particular pre-
ilation was mandatory, and stent implantation was per-
ormed at a pressure not exceeding the rated burst pressure.
ost-dilation was left to the operator’s discretion; however,
f post-dilation was performed, balloons were required to be
horter than the length of the deployed stent. In the event
f a bailout procedure and the need for an additional stent,
he stent was required to be of the same type as the first
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
CI  confidence interval
CK-MB  creatinine kinase-
myocardial band
DES  drug-eluting stent(s)
DS  diameter stenosis
EES  everolimus-eluting
stent(s)
HR  hazard ratio
ID-TLR  ischemia-driven
target lesion
revascularization
IVUS  intravascular
ultrasound
MACE  major adverse
cardiovascular events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
RR  relative risk
SES  sirolimus-eluting
stent(s)
ULN  upper limit of normal
TVF  target vessel failure
TVR  target vessel
revascularizationmplanted stent.
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1192In a subset of 152 consecutive patients enrolled in
re-selected centers, intravascular ultrasound (IVUS) was
erformed after optimal stent placement had been achieved.
eriprocedural pharmaceutical treatment was administrated
ccording to standard hospital practice. Procedural antico-
gulation was achieved with unfractionated heparin or
ivalirudin. The use of glycoprotein IIb/IIIa inhibitors was
eft to the operator’s discretion. All patients enrolled into
he study were to receive 75 mg of aspirin daily for a
inimum of 1 year and clopidogrel 75 mg for a minimum
f 6 months after the index procedure.
ollow-up. Patient review was initially planned at 1, 6, 9,
2, and 24 months after the index procedure; however, a
ubsequent protocol amendment enabled further clinical
valuation to be performed on an annual basis out to 5 years.
t outpatient visits, patients were specifically questioned
bout the development of angina or the occurrence of any
dverse events. Angiographic follow-up for all patients was
lanned at 180 days, with IVUS planned in a subset of 152
onsecutive patients (from selected centers). Angiography
nd IVUS were repeated after 2 years in these 152 consec-
tive patients.
tudy end points. The clinical end point of this 3-year
ollow-up study was MACE, defined as a composite of
ardiac death, MI, and ischemia-driven target lesion revas-
Table 1. Baseline Characteristics of the Patient Popu
(n 
Age (yrs) 62
Male (%)
Current smoker (%)
Diabetes (%)
Hypertension-requiring medication (%)
Hyperlipidemia-requiring medication (%)
Prior target vessel intervention (%)
Prior MI (%)
Stable angina (%)
Unstable angina (%)
Target Vessel (%) n  260
Left anterior descending 4
Left circumﬂex 2
Right coronary artery 3
AHA/ACC lesion class (%)
A
B1 2
B2 6
C 1
Reference vessel diameter (mm  SD) 2.70
Lesion length (mm  SD) 13.0
There was no significant difference between the everolimus and pacli
AHA/ACC American Heart Association/American College of Cardpaclitaxel-eluting stent(s).ularization (ID-TLR) by coronary artery bypass graft
urgery (CABG) or PCI. Secondary clinical end points
ncluded target vessel failure (TVF), a composite of cardiac
eath, MI, ID-TLR, and non–target lesion ischemia-driven
arget vessel revascularization (ID-TVR). An independent
linded clinical events committee (CEC) evaluated all
linical end points, and a data and safety monitoring board,
ot affiliated with the study, ensured the safe conduct of the
rial.
eﬁnitions. All deaths were considered cardiac unless an
ndisputed noncardiac cause was present. The onset of the
rial was before the publication of the Academic Research
onsortium’s (ARC) consensus definitions for DES study
nd points, and therefore the only cardiac enzymes available
n all patients to adjudicate events were creatinine kinase
CK), and creatinine kinase-myocardial band (CK-MB)
15). Q-wave MI was defined as the development of new
athological Q waves. A non–Q-wave MI was defined as a
ypical rise and fall of CK-MB, with at least 1 of the
ollowing: ischemic symptoms; electrocardiographic
hanges indicative of ischemia (ST-segment elevation or
epression); or an associated coronary artery intervention.
or a nonprocedural/spontaneous MI the CK-MB was
equired to be 2 times the upper limit of normal (ULN).
CK-MB 3 times the ULN or 5 times the ULN was
)
PES
(n  77)
All Patients
(n  300)
62 9 62 10
79 73
30 31
24 23
65 67
75 70
4 4
25 32
62 62
32 28
ns n  91 Lesions n  351 Lesions
47 42
19 26
34 31
0 1
20 21
67 66
13 13
2.82 0.58 2.73 0.54
13.2 6.4 13.0 5.9
atment arms.
EES everolimus eluting stent(s); MImyocardial infarction; PESlation
EES
223
 10
71
32
23
67
69
4
35
62
27
Lesio
1
9
0
1
1
5
3
0.52
5.7
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1193equired for an MI to be defined post-PCI or post-CABG,
espectively.
The ID-TLR was defined as revascularization of the target
esion in association with any of the following: a positive test of
schemia, with either exercise testing or fractional/coronary
ow reserve; ischemic symptoms and an angiographic DS
Figure 1. Clinical Follow-Up of Patient Population
Flow chart indicating the ﬂow of patients through the study. In total 264 (88%
follow-up, which was similar in both groups, was failure to sign a new consen
5 years.
Table 2. Hierarchical Subject Counts of Adverse Even
0–1,095 Days
% (n)
EES
(n  223)
MACE 7.2 (14/195)
TVF 11.8 (23/195)
Cardiac death 0.5 (1/195)
MI 3.6 (7/195)
Q-wave MI 0.0 (0/195)
Non–Q-wave MI 3.6 (7/195)
ID-TLR 3.1 (6/195)
ID-TLR CABG 0.0 (0/195)
ID-TLR PCI 3.1 (6/195)
ID-TVR (nontarget lesion) 4.6 (9/195)
ID-TVR CABG 0.5 (1/195)
ID-TVR PCI 4.1 (8/195)
Intent-to-treat population. Target vessel failure (TVF): composite of car
larization (ID-TLR), ischemia-driven target vessel revascularization (ID-T
hypothesis-testing and are displayed for descriptive purposes only. Sub
MI, non–Q-waveMI, ID-TLR coronary artery bypass graft surgery (CABG
PCI. This table includes revascularizations on any target vessels(s)/les
analysis plan, because the composite TVF and major adverse cardiova
deaths only, patients with noncardiac deaths were excluded from theCI confidence interval; NC not calculable; other abbreviations as in Tab50% by online quantitative coronary angiography; or DS
70% by online quantitative coronary angiography without
schemic symptoms or a positive functional study.
The protocol for stent thrombosis changed after the
ublication of the ARC definitions for stent thrombosis
15). Those stent thrombotic events occurring before the
nts attended for 3 years of follow-up (f/u). The major reason for the loss of
after the protocol amendment allowing study follow-up to be extended to
rough 3 Years
PES
n  77)
Relative Risk
(95% CI) p Value*
.9 (11/69) 0.45 (0.21–0.94) 0.053
.4 (12/69) 0.68 (0.36–1.29) 0.30
.3 (3/69) 0.12 (0.01–1.12) 0.056
.3 (3/69) 0.83 (0.22–3.10) 0.72
.0 (0/69) NC (NC) NC
.3 (3/69) 0.83 (0.22–3.10) 0.72
.2 (5/69) 0.42 (0.13–1.35) 0.16
.0 (0/69) NC (NC) NC
.2 (5/69) 0.42 (0.13–1.35) 0.16
.4 (1/69) 3.18 (0.41–24.68) 0.46
.0 (0/69) NC (NC) 1.00
.4 (1/69) 2.83 (0.36–22.22) 0.45
ath, myocardial infarction (MI), ischemia-driven target lesion revascu-
ntarget lesion). All p values displayed are 2-tailed and not from formal
e only countedonce in the hierarchical order of cardiac death, Q-wave
R percutaneous coronary intervention (PCI), ID-TVR CABG, and ID-TVR
r subjects with 2 target vessels/lesions treated. As per the statistical
vent (MACE) (cardiac death, MI, ID-TLR) end points included cardiac
inator. *From Fisher exact test.) patie
t formts Th
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1194doption of the ARC definitions were re-adjudicated by the
EC to the new guidelines.
tatistical methods. The rationale for sample size calcula-
ions for this study has previously been reported (13). In this
rticle, binary variables are presented as percentages and
ompared with the Fisher exact test. All analyses are by
ntention-to-treat with all patients randomized in the study,
egardless of the treatment actually received. However, patients
ho were lost to follow-up, in whom no event had occurred
efore the follow-up windows, were not included in the
enominator for calculations of binary end points. Survival
urves were constructed for time-to-event variables with
aplan-Meier estimates and compared by the log-rank test.
tatistical analyses were performed with the SAS statistical
ackage (version 9.1.3, SAS Institute, Cary, North Carolina).
esults
atient population and lesion characteristics. The baseline
emographic, clinical, and angiographic characteristics of
Table 3. Nonhierarchical Subject Counts of Adverse E
0–1,095 Days
% (n)
EES
(n  223)
All death 4.4 (9/203)
Cardiac death† 0.5 (1/195)
MI† 3.6 (7/195)
Q-wave MI† 0.0 (0/195)
Non–Q-wave MI† 3.6 (7/195)
Any ID-TVR (including ID-TLR)† 9.2 (18/195)
CABG† 1.0 (2/195)
PCI† 8.7 (17/195)
All TLR 5.4 (11/203)
CABG 0.5 (1/203)
PCI 5.4 (11/203)
ID-TLR† 4.6 (9/195)
CABG† 0.5 (1/195)
PCI† 4.6 (9/195)
Non-ID TLR 1.5 (3/203)
CABG 0.0 (0/203)
PCI 1.5 (3/203)
ID-TVR, nontarget lesion† 5.1 (10/195)
CABG† 0.5 (1/195)
PCI† 4.6 (9/195)
Non-ID TVR, nontarget lesion 2.0 (4/203)
CABG 1.0 (2/203)
PCI 1.0 (2/203)
Any TVR (including TLR) 11.3 (23/203)
CABG 2.0 (4/203)
PCI 9.9 (20/203)
Intent-to-treat population. This table includes revascularizations on an
All p valuesdisplayedare 2-tailed andnot from formal hypothesis testin
per the statistical analysis plan, because the composite TVF andMACEe
excluded from the denominator.Abbreviations as in Tables 1 and 2.oth treatment groups have been published previously (16)
nd are summarized in Table 1. No significant differences
ere present in any of the parameters listed.
Figure 1 shows the clinical follow-up of patients from
nrolment to 3 years, on an intention-to-treat basis. Overall
linical assessment (on the basis of TVF) was available in
64 patients (88%), made up of 195 of the original 223 EES
atients (87.4%) and 69 of the original 77 PES patients
89.6%). The reasons for incomplete follow-up are shown in
igure 1. A similar proportion in each stent group were lost
ecause of failure to complete a new consent form, which
as required after a change in the initial protocol to allow
xtended follow-up out to 5 years. Four patients withdrew
rom the EES group, of which 1 experienced a noncardio-
ascular event occurring 1-year after PCI; the other 3
atients were all event-free at last contact.
The angiographic outcomes at 6 months and 2 years and
he clinical outcomes at 6 months, 1 year, and 2 years have
ll been presented elsewhere (10,11,16). In brief, at 6
Through 3 Years
PES
(n  77)
Relative Risk
(95% CI) p Value*
9.6 (7/73) 0.46 (0.18–1.20) 0.14
4.3 (3/69) 0.12 (0.01–1.12) 0.056
7.2 (5/69) 0.50 (0.16–1.51) 0.31
0.0 (0/69) NC (NC) NC
7.2 (5/69) 0.50 (0.16–1.51) 0.31
13.0 (9/69) 0.71 (0.33–1.50) 0.36
0.0 (0/69) NC (NC) 1.00
13.0 (9/69) 0.67 (0.31–1.43) 0.35
12.3 (9/73) 0.44 (0.19–1.02) 0.06
0.0 (0/73) NC (NC) 1.00
12.3 (9/73) 0.44 (0.19–1.02) 0.06
10.1 (7/69) 0.45 (0.18–1.17) 0.14
0.0 (0/69) NC (NC) 1.00
10.1 (7/69) 0.45 (0.18–1.17) 0.14
5.5 (4/73) 0.27 (0.06–1.18) 0.08
0.0 (0/73) NC (NC) NC
5.5 (4/73) 0.27 (0.06–1.18) 0.08
4.3 (3/69) 1.18 (0.33–4.16) 1.00
0.0 (0/69) NC (NC) 1.00
4.3 (3/69) 1.06 (0.30–3.81) 1.00
1.4 (1/73) 1.44 (0.16–12.66) 1.00
0.0 (0/73) NC (NC) 1.00
1.4 (1/73) 0.72 (0.07–7.81) 1.00
15.1 (11/73) 0.75 (0.39–1.46) 0.41
0.0 (0/73) NC (NC) 0.58
15.1 (11/73) 0.65 (0.33–1.30) 0.28
t vessels(s)/lesion(s) for subjects with 2 target vessels/lesions treated.
re displayed for descriptivepurposes only. *FromFisher exact test. †As
ts included cardiac deaths only; patientswith noncardiac deathswerevents
y targe
ganda
ndpoin
m
l
w
M
b
c
d
t
l
o
C
n
s
t
I
n
0
a
a
o
d
f
(
(
w
u
(
1
t
w
t
p
P
f
s
o
9
p
s
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 2 , 2 0 0 9 Garg et al.
D E C E M B E R 2 0 0 9 : 1 1 9 0 – 8 3-Year Follow-Up of the SPIRIT II Study
1195onths EES demonstrated significantly reduced in-stent
ate loss and percentage volume obstruction when compared
ith PES (p  0.001). Clinical outcomes in terms of
ACE, TVF, MI, cardiac death, and ID-TLR were all
etter with EES at 6 months, 1 year, and 2 years when
ompared with PES. Angiographic follow-up at 2 years
emonstrated a late increase in neointimal hyperplasia with
he EES stent, such that a significant difference was no
onger observed between EES and PES for in-stent late loss
r percentage volume obstruction.
linical outcomes at 3-year follow-up. The hierarchical and
on-hierarchical events at 3-year clinical follow-up are
hown in Tables 2 and 3, respectively; and Figure 26 shows
he Kaplan-Meier survival curves for cardiac death, MI,
D-TLR, and MACE.
At 3-year follow-up, the use of EES was associated with
onsignificant reductions in cardiac death, (relative risk [RR]:
.12, 95% confidence interval [CI]: 0.01 to 1.12, p  0.056)
ll-cause death (RR: 0.46, 95% CI: 0.18 to 1.20, p  0.14),
nd MI (RR: 0.50, 95% CI: 0.16 to 1.51, p 0.31). The rates
f MI were consistently higher with PES; however, this
Figure 2. Kaplan-Meier Event Curves at 3-Year Follow-Up
Kaplan-Meier event curves at 3 years follow-up for (A) myocardial infarction (M
(D) major adverse cardiovascular events (MACE). HR  hazard ratio; NA  not applicifference did not reach significance at any time during
ollow-up.
During the 3-year follow-up period, 7 PES patients
10.1%) and 9 EES patients (4.6%) underwent ID-TLR
RR: 0.45, 95% CI: 0.18 to 1.17, p  0.14). All of these
ere with PCI, apart from 1 patient in the EES group who
nderwent CABG. The Kaplan-Meier curve for ID-TLR
Fig. 2B) shows significantly lower ID-TLR with EES at
-year follow-up; however, this significance was not main-
ained during long-term follow-up.
The rate of MACE (cardiac death, MI, ID-TLR), which
as 7.2% in those patients treated with EES and 15.9% in
hose treated with PES (RR: 0.45, 95% CI: 0.21 to 0.94,
 0.053), was consistently lower for EES compared with
ES; however, the difference between the 2 varied with
ollow-up. As shown on the Kaplan-Meier curve (Fig. 2), a
ignificant difference in MACE between the 2 stents was
bserved as early as 12 months (EES vs. PES, 2.7% vs.
.1%, hazard ratio [HR]: 0.29, 95% CI: 0.10 to 0.87,
logrank  0.018); however, between years 1 and 2 EES
eemed to “catch-up.” Nevertheless, a significant difference
ischemia-driven target lesion revascularization (TLR), (C) cardiac death, andI), (B)
able.
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1196e-emerged by the third year of follow-up (EES vs. PES,
.4% vs. 14.9%, HR: 0.43, 95% CI: 0.19 to 0.94, plogrank 
.029), which was the result of 3 additional patients with
ACE observed in the PES group, whereas no new
atients experienced MACE in the EES group.
The rates of stent thrombosis as per ARC definitions are
isted in Table 4. After the 2-year follow-up, no definite/
robable stent thrombosis occurred in the EES group,
ompared with 1 in the PES group. Overall, at 3-year
ollow-up the rate of stent thrombosis was numerically
ower in the EES group (1.0% vs. 2.9%, p  0.28). The
roportion of patients returning for 3-year follow-up, who
emained on dual antiplatelet therapy at 3 years, was 14.1%
nd 21.2% for patients treated with EES and PES, respec-
ively (Fig. 3).
iscussion
his randomized prospective study of the EES has confirmed
ts favorable clinical outcomes at 3-year follow-up and en-
ances the work of the previous EES studies (5–8,17).
In the present study, patients randomized to EES expe-
ienced fewer MIs, fewer ID-TLR, and had a trend for less
ardiac death compared with those patients treated with
ES. The overall rates of both MACE and TVF were
umerically lower in favor of EES. These 3-year results
emonstrate the maintenance of the superior outcomes with
ES, which were observed as early as 6 months (13).
Two-year outcome data from SPIRIT II showed the
aintenance of the advantage of EES over PES; however,
Rs were less prominent than previously observed at 12
onths (11). Furthermore, the results of 2-year angio-
raphic follow-up in 97 EES patients demonstrated a 94%
ncrease in the mean in-stent late loss among EES between
months and 2 years (0.17  0.32 mm vs. 0.33  0.37
m), whereas a 3% increase was observed with PES over
he same time period (0.33  0.32 mm vs. 0.34  0.34
m). It is worth noting, however, that angiographic
ollow-up at 2 years was in a subset and not the entire
PIRIT II population, and as such, an unintended selection
Table 4. Stent Thrombosis Events by ARC Definitions
Definite and Probable EES PES
Acute stent thrombosis (%) 0.0 0.0
Subacute stent thrombosis (%)
(24 h–30 days)
0.0 1/77 (1.3)*
Late stent thrombosis (%)
(30 days–1 yr)
0.0 1/77 (1.3)*
Very late stent thrombosis (%)
(1 yr)
2/193 (1.0) 1/67 (1.5)
Total stent thrombosis 2/193 (1.0) 2/68 (2.9)
Values are n (%). *Same patient.
ARC Academic Research Consortium; other abbreviations as in Table 1.ias in this subset cannot be ruled out.Nevertheless, concerns were raised as to the clinical rele-
ance of this “late-catch up phenomenon” that was observed
ith EES. The present study, however, confirms that this
ncrease in neointimal hyperplasia did not translate into any
linical events. In fact, between years 2 and 3, 2 ID-TLR were
erformed for EES (1 of which in a patient who already had
D-TLR before 6 months), and similarly, 2 ID-TLR were
erformed for PES. The absolute difference in rates of ID-
LR between EES and PES actually increased from 4.7% at
year to 5.2% at 3 years (Fig. 2). In addition, no cardiac deaths
ccurred with EES between years 2 and 3. Of note, the
aplan-Meier curves for MACE and all its components at 3
ears seem to diverge, further supporting the superior perfor-
ance of the EES with long-term follow-up.
The much larger SPIRIT III trial randomized EES to
ES in a 2:1 ratio and enrolled 1,002 patients with similar
nclusion and exclusion criteria. The demographic data of
oth patient populations were similar. The SPIRIT III trial
gain confirmed the superior performance of EES compared
ith PES with long-term follow-up with a 45% reduction
n MACE at 2 years (7.3% vs. 12.8%; HR: 0.55; 95% CI:
.36 to 0.83, p 0.004). Importantly, and unlike in SPIRIT
I, there was no reduction in HRs between 1 and 2 years; in
act, the clinical benefits of EES seem to increase (12).
Although the current study is underpowered to make any
efinitive conclusions regarding stent thrombosis rates be-
ween EES and PES, it does confirm low rates of late stent
hrombosis with EES (1.0%), which is comparable to
ublished data for sirolimus-eluting stents (SES) and PES,
t similar follow-up (18). Historically, first-generation DES
ave been associated with a persistent risk of very late stent
Figure 3. Cumulative Duration of DAPT in Patients With 3-Year Follow-Up
Graph demonstrating the cumulative use of dual antiplatelet therapy
(DAPT) among the 264 patients who returned for 3-year follow-up. In total,
14.1% of patients treated with everolimus-eluting stents and 21.2% of
patients treated with paclitaxel-eluting stents were still receiving DAPT at
1,080 days of follow-up.
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1197hrombosis, extending out to 4-year follow-up (18); how-
ver, this might not be the same for the newer generation of
ES such as the XIENCE V. In the current study EES has
emonstrated no episodes of acute or late stent thrombosis, 2
pisodes (1 definite and 1 probable) of very late stent throm-
osis between year 1 and year 2, and no stent thrombosis events
fter 2 years. Similarly, the SPIRIT III trial demonstrated a
ow rate of very late (0.3%) and overall stent thrombosis (1.3%)
ith EES. The relationship of the late loss catch-up, if any,
ith lower late stent thrombosis is unclear; it is possible that
eointimal healing, reflected as a modest increase in late loss
ver time, might in fact be protective.
The SES has been demonstrated to be the most effica-
ious first-generation DES (19–21), and therefore, the use
f PES in this study might account for the favorable
utcomes observed with EES. In principle, because both
verolimus and sirolimus inhibit the mammalian target of
apamycin in a similar manner, a comparison between the 2
ight demonstrate similar clinical outcomes. Indirect com-
arisons do support this; for example, similar rates of late
oss occurred in the EES arm of the SPIRIT III trial and
he SES arm of the SIRIUS (Sirolimus-Eluting Stent in de
ovo Native Coronary Lesions) trial (EES 0.16 mm vs. SES
.17 mm) (9,22); however, as yet no randomized head-to-
ead comparison has been made between the 2 stents. There
re, in addition to the antiproliferative coating, other notable
ifferences between the stents, which might result in different
linical outcomes. In brief, EES is made of cobalt chromium,
s opposed to stainless steel (PES and SES), which allows
omparative radial strength to be achieved with considerably
hinner stent struts. This can reduce vascular injury, intimal
yperplasia, and the risk of restenosis (23). Vascular injury and
nflammation are also potentially reduced with the use of more
iocompatible polymers as found on the EES, compared with
he durable and less biocompatible polymers found on the PES
nd SES.
A clearer picture will be obtained when the results of the
rospective, randomized, multicenter EXCELLENT (Effi-
acy of Xience/promus versus Cypher in rEducing Late Loss
fter stENTing) trial are available. This study is enrolling
pproximately 1,400 patients with the aim of comparing the
afety and efficacy of the EES and SES and the optimal
uration of dual antiplatelet therapy (6 or 12 months). The
o-primary end points are the noninferiority of EES compared
ith SES in inhibiting neointima hyperplasia and preventing
ate loss at 9 months and TVF at 12 months for comparison of
ual antiplatelet therapy duration (24). Furthermore, additional
tudies of the EES include the SPIRIT IV, SPIRIT V, XIENCE
SPIRIT WOMEN, XIENCE V USA, and XIENCE V
NDIA, which are all designed to evaluate the safety and efficacy
f the EES in over 14,000 real-world patients.
tudy limitations. This study was not powered to detect
ignificant differences in the safety profiles of either stent. In
iew of the small number of patients recruited and the lossf 8% of patients from follow-up (which was similar in both
roups), caution is required when interpreting the differ-
nces in events.
onclusions
he present study reports the favorable 3-year clinical out-
omes of the EES, which are consistent with the results from
arlier studies with shorter follow-up. In this study, compared
ith the PES, the EES demonstrated a reduction in cardiac
vents, clinical restenosis, and overall MACE rate at long-term
ollow-up. In addition, the overall lower rate of stent throm-
osis and absence of stent thrombosis after 2 years with EES
s potentially significant and requires additional investigation.
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